Advertisement

Topics

Latest "Hakushindo Pharmaceutical Co., Ltd." News Stories

08:10 EST 20th February 2019 | BioPortfolio

Here are the most relevant search results for "Hakushindo Pharmaceutical Co., Ltd." found in our extensive news archives from over 250 global news sources.

More Information about Hakushindo Pharmaceutical Co., Ltd. on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Hakushindo Pharmaceutical Co., Ltd. for you to read. Along with our medical data and news we also list Hakushindo Pharmaceutical Co., Ltd. Clinical Trials, which are updated daily. BioPortfolio also has a large database of Hakushindo Pharmaceutical Co., Ltd. Companies for you to search.

Showing "Hakushindo Pharmaceutical" News Articles 1–25 of 8,300+

Wednesday 20th February 2019

eRace Cancer Says 78-Year-Old Don Wright—a 16-Year Cancer Survivor—to Run in Iowa Senior Games on February 23rd as He Gears up for the National Senior Games in June

Don aims to improve his times in four events, while able to do so because of new medications that keep his cancer in check eRace Cancer, a social media campaign to educate patients about advances and innovations in cancer treatments, said that Don Wright, now 78 years old, will be running in the Iowa Senior Games on Saturday, February 23, in Rock Islan...


Novus Therapeutics to Participate in the 8th Annual SVB Leerink Global Healthcare Conference

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that the company will participate at the 8th Annual SVB Leerink Healthcare Conference on Thursday, February 28, 2019 at the Lotte New York Palace, New York. About...

Cerevel Therapeutics Appoints Raymond Sanchez, M.D., as Chief Medical Officer

Will oversee the clinical development and regulatory submissions for company’s extensive pipeline, including two late-stage programs for the treatment of central nervous system disorders Cerevel Therapeutics, a biopharmaceutical company focused on developing new medicines to treat disorders of the central nervous system (CNS), today announced ...


Peloton Therapeutics Secures $150 Million in Series E Financing

- Proceeds to advance oral HIF-2α inhibitor, PT2977, into Phase 3 trial in advanced renal cell carcinoma – - Financing led by RA Capital Management - Peloton Therapeutics, Inc., a drug discovery and development company advancing first-in-class oral medicines for cancer and other serious conditions, today announced the closing of an oversubs...

PPD and HLT to Create Data Science-Driven Clinical Research Solutions in China to Enhance Global Drug Development

Unique collaboration pairs HLT’s data technology and artificial intelligence with PPD’s global expertise in clinical trials and real-world evidence generation Pharmaceutical Product Development, LLC (PPD) and Happy Life Tech (

Newron Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference

Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that Stefan Weber, CEO, will present at the 8th Annual SVB Leerink Global Healthcare Conference in New York, NY on Wednesday, Februa...

The Medicines Company to Announce Fourth-Quarter and Full-Year 2018 Financial Results on February 27

The Medicines Company (NASDAQ:MDCO) will host a conference call and audio webcast on Wednesday, February 27, 2019, at 8:30 a.m. EST to discuss its fourth-quarter and full-year 2018 financial results and operational developments. The conference call may be accessed by telephone as follows:   ...

Rocket Pharmaceuticals Announces Participation in Fireside Chat at the 8th Annual SVB Leerink Global Healthcare Conference

Rocket Pharmaceuticals, Inc. (Nasdaq: RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today announces that Gaurav Shah, M.D., Chief Executive Officer and President of Rocket, will participate in a fireside chat at the 8th Annual SVB Leerink Global Healthcare Conference in New York City. The fireside chat will take pla...

Recursion Named to Fast Company’s Annual List of the World’s Most Innovative Companies

Recursion, a clinical-stage biotechnology company that combines artificial intelligence (AI), experimental biology, and automation to discover and develop drugs at scale, has been named to Fast Company’s annual list of the World’s Most Innovative Companies for 2019. The list honors the businesses making the most profound impact on both industry ...

Microreactor Technology Adoption to Spur as an Optimal Time-to-Market Enabler and Effective Solution in Pharmaceutical Drug Synthesis

A recent research study by Fact.MR finds that the microreactor sales reached approximately 294 thousand units in 2018 and are projected to grow at a Y-O-Y of nearly 9% in 2019. Increasing competition among manufacturers to develop efficient products remains a key aspect spurring the demand for microreactor technology. Enablement in facilitating effective and efficient drug synthesis is one of the ...

Mogrify Raises $3.7 Million USD Seed Funding to Accelerate Its Mission to Transform Cell Therapy via Direct Cellular Conversion

Darrin M Disley, PhD, DSc, OBE, appointed as CEO New investment from Ahren Innovation Capital, 24Haymarket and Dr Disley Mogrify’s technology enables the conversion of any mature cell type into any other mature cell type without going through a pluripotent stem cell- or progenitor cell-state ...

GENSPEED Biotech: Novel Point-of-Care Testing Technology Enables Rapid Test for Medical Risk Classification

Austrian GENSPEED Biotech GmbH and Virogates A/S (Nasdaq First North Denmark: VIRO) have commenced a partnership to develop a rapid test for the risk classification of acute and chronic patients on site. The test targets to simultaneously analyze for C- Reactive Protein and suPAR from a finger prick in less than 10 minutes. Immediate results suppo...

Bicycle Therapeutics Strengthens Executive Team with Key Changes

Peter Leone Appointed Chief Business Officer Lee Kalowski, Chief Financial Officer, Promoted to U.S. President Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, today announced several key changes to its executive team, including t...

Roche secures FDA priority review for entrectinib and polatuzumab vedotin

Entrectinib has been granted priority review for the treatment of neurotrophic tropomyosin receptor kinase (NTRK) fusion-positive, locally advanced or metastatic solid tumors in adult and paediatric patients. The The post Roche secures FDA priority review for entrectinib and polatuzumab vedotin appeared first on Pharmaceutical Business review.

Merck gets FDA nod for Keytruda as adjuvant treatment for melanoma

The recommended dose of Keytruda for the adjuvant treatment of adult patients with melanoma is 200 mg administered as an intravenous infusion over 30 minutes every three weeks The post Merck gets FDA nod for Keytruda as adjuvant treatment for melanoma appeared first on Pharmaceutical Business review.

Pfizer secures approval from European Commission for Avastin biosimilar

“Pfizer is dedicated to increasing access to biosimilars for patients suffering from serious illnesses and helping create a more sustainable healthcare system,” said Andreas Penk, M.D., regional president, The post Pfizer secures approval from European Commission for Avastin biosimilar appeared first on Pharmaceutical Business review.

Global MicroPump Market Research Report 20122024 [Report Updated: 01011970] Prices from USD $1800

The global MicroPump market will reach Volume Million USD in 2017 with CAGR xx% 20192023. The objective of report is to define, segment, and project the market on the basis of product type, application, and region, and to describe the content about the factors influencing market dynamics, policy, economic, technology and market entry etc.Based on products type, the report describes major products ...

Drug Patent Expirations for the Week of February 17, 2019

ZOSYN IN PLASTIC CONTAINER (piperacillin sodium; tazobactam sodium) Wyeth pharms Patent: 6,207,661 Expiration: Feb 22, 2019 See More … For more information on how DrugPatentWatch can help with your pharmaceutical… The post Drug Patent Expirations for t... The post Drug Patent Expirations for the Week of February 17, 2019 appeared first on Biotechblog.

Which pharmaceutical companies have the most gum dosed drugs?

This chart shows the pharmaceutical companies with the most gum dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most gum dosed drugs… The post Which pharmaceutical companies have the most gum dosed dr... The post Which pharmaceutical companies have the most gum dosed drugs? appeared first on Biotechblog.

Tuesday 19th February 2019

University of Dundee partners with Takeda to develop new treatments for tau pathology

The University of Dundee Drug Discovery Unit has announced a partnership with Takeda, Japan's largest pharmaceutical company, to develop possible new therapeutic treatments for tau pathology, an underlying feature in several forms of neurodegeneration, including Alzheimer's disease.

Pfizer’s new partnership focuses on digitising clinical trials

Pfizer has partnered with non-profit healthcare system Ochsner Health System to develop digital models that aim to improve clinical trials....Read More... The post Pfizer’s new partnership focuses on digitising clinical trials appeared first on Pharmaceutical Technology.

FDA agrees to review AbbVie’s upadacitinib in rheumatoid arthritis

The US Food and Drug Administration (FDA) has accepted a new drug application (NDA) submitted by AbbVie for its investigational...Read More... The post FDA agrees to review AbbVie’s upadacitinib in rheumatoid arthritis appeared first on Pharmaceutical Technology.

Ultragenyx Pharmaceutical's (RARE) CEO Emil Kakkis on Q4 2018 Results - Earnings Call Transcript

Teva Finalizes Settlement with Federal Trade Commission to Resolve All Outstanding Litigation between the Parties

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced a settlement with the Federal Trade Commission (FTC) that will resolve all outstanding litigation between the parties. Under the terms of the settlement, which is subject to court approval, the FTC will dismiss its claims against Teva and its affiliates in three outstanding cases, an...

Veteran 3M Scientist Reflects on the Past, Present and Future of Drug Delivery R&D

ArticleAfter recently retired from a career at 3M spanning more than thirty years in drug delivery systems R&D, a scientist shares some thoughts and impressions on the industry.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks